Overview

* EyePoint Q2 revenue falls to $5.3 mln from $9.5 mln year-over-year

* Operating expenses rise to $67.6 mln due to DURAVYU trial costs

* Net loss widens to $59.4 mln from $30.8 mln in prior year

Outlook

* EyePoint expects cash reserves to fund operations into 2027

* Company anticipates topline Phase 3 data for DURAVYU in 2026

* EyePoint preparing for potential NDA filing with registration batches

* Company sees DURAVYU first-to-market among sustained release treatments

Result Drivers

* TRIAL COSTS - Increase in operating expenses attributed to DURAVYU Phase 3 trial costs for wet AMD

* REVENUE DECLINE - Revenue decrease due to lower recognition of deferred revenue from YUTIQ product rights license

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $5.33

Product mln

Sales

Q2 Net -$59.43

Income mln

Q2 Basic -$0.85

EPS

Q2 $67.56

Operatin mln

g

Expenses

Q2 -$62.23

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for EyePoint Pharmaceuticals Inc ( EYPT ) is $27.50, about 60.4% above its August 5 closing price of $10.89

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)